危险因素对宫颈癌发生危险度的交互作用及HPV基因型与宫颈癌及其癌前病变关系的研究
|
摘要
[目的]
研究高危型HPV基因型与宫颈癌及宫颈癌前期病变的关联；探讨性传播病原体感染及其DNA负荷量对宫颈癌发生的作用；探讨宫颈癌发病的危险因素,以及性传播病原体感染、行为因素在HPV致癌中的交互作用。[方法]
1、采用病例-对照研究设计,对每位研究对象(308例宫颈癌病例、336例对照)行宫颈癌危险因素调查,取宫颈细胞标本及采集6ml血样。提取宫颈细胞DNA,行HPV DNA、HCMV、HSV-Ⅱ、CT、UU和NG的检测。血清标本用于TP及HIV检测。研究本地区HR-HPV与宫颈癌的关系,性传播病原体感染及其DNA负荷量对宫颈癌发生的作用以及性传播病原体感染、行为因素与HPV致癌的交互作用。
2、对2338位妇女行宫颈三阶梯诊疗程序筛查及HPV DNA检测,以组织病理学检查为金标准,分析HR-HPV基因型与宫颈病变的关系。对因CINⅡ／Ⅲ行LEEP治疗且宫颈切缘阴性的236位患者随访2年。所有患者在LEEP术前,术后6个月,1年和2年取宫颈细胞行HPV DNA检测。探讨HPV基因型与CIN治疗后残留／复发的关系。
[结果]
1、HR-HPV基因型与宫颈癌发生危险性分析：HR-HPV-16(OR=51.55；95%CI=28.73-61.86)、HR-HPV-18(OR=52.81;95%CI=22.84-61.27)、HR-HPV-31(OR=12.41；95%CI=10.59-16.68)、HR-HPV-53(OR=2.92;95%CI=1.03-8.28)、HR-HPV-59(OR=13.58；95%CI=10.76-21.07)、HR-HPV多重感染(OR=1.11；95%CI=0.81-3.13)。HR-HPV-33、HR-HPV-39、HR-HPV-45仅在宫颈癌病例中检出。
2、性传播病原体感染与宫颈癌发生的危险性分析：HCMV(OR=7.106；95%CI=3.479-14.512)；HSV-Ⅱ(OR=32.489；95%CI=7.514-40.478)；CT(OR=12.315;95%CI=5.824-26.039)；UU(OR=4.564；95%CI=3.177-6.556)；NG(OR=1.662；95%CI=0.427-6.467)；TP(OR=21.104；95%CI=7.324-60.816)。HCMV、UU的DNA负荷量在宫颈癌组及对照组,差异有统计学意义(P<0.001)；HSV-Ⅱ、CT、NG的DNA负荷量在宫颈癌组及对照组,差异无统计学意义(P＞0.05)。
3、宫颈癌的危险因素：结核病史(OR=4.388；95%CI=1.846-10.426)、性传播疾病史(OR=20.501;95%CI=7.097-59.226)、怀孕次数多、初次性关系年龄小(16-20岁)、性伴侣数≥3、HR-HPV、HSV-Ⅱ、TP感染。
4、HPV基因型与宫颈癌及癌前期病变的危险性分析：与CINⅠ有关：HPV-66、-68、-CP8304；与CINⅡ／Ⅲ有关：HPV-52。
5、HR-HPV基因型与CIN治疗后残留／复发的关系：治疗前HPV亚型为HR-HPV-16(P=0.007)、HR-HPV-18(P=0.000)、HR-HPV-33(P=0.001)、HR-HPV-45(P=0.019)和HR-HPV多重感染(P=0.005),术后残留／复发率高。
[结论]
1、本地区宫颈癌高危HPV基因型是：HPV-16、-18、-31、-33、-39、-45、-53、-59。感染HPV-18、HPV-16发生宫颈癌的风险最高。
2. HCMV、HSV-Ⅱ、CT、UU、TP感染与宫颈癌发生有关,HCMV、HSV-Ⅱ、CT、UU、TP感染与HPV感染对宫颈癌发生有联合作用,HCMV、TP感染与HPV感染对宫颈癌发生未见交互作用,感染病原体种类数与HPV致癌有联合作用。
3、结核病史、性传播疾病史、怀孕次数多、初次性关系年龄小(16-20岁)、性伴侣数≥3、HR-HPV、HSV-Ⅱ、TP感染是福建地区宫颈癌的主要危险因素。性传播疾病、孕次、性伴侣数在宫颈癌的发生中有联合作用。
4、高危型HPV多重感染无明显增加宫颈癌及癌前病变的风险。
5、感染HPV-66,-68和-CP8304与发生CINⅠ有关,感染HPV-52与发生CINⅡ／Ⅲ有关。CINⅡ／Ⅲ治疗前感染亚型为HPV-16、-18、-33、-45以及HR-HPV多重感染,与治疗后残留／复发的发生有关。
[Objective]
To study the association of HR-HPV genotype with cervical cancer and precancerous lesions, the relation of infections of sexually transmitted pathogenic microbes with cervical cancer, risk factors of cervical cancer in Fujian and the synergistic action of pathogen microbes and behavial factor in etiology of cervicle cancer.
[methods]
1. A case-control design was applied in this study. A total of 308 patients of cervical cancer diagnosed with histology were enrolled and 336 control subjects consisted of patients of hysterectomy with benign lesions. Each participant was scheduled for a face-to-face interview with the structured questionnaire. Cervical cells were obtained and 6 ml blood was collected from all women. Cervical cells DNA was extracted, and HPV DNA、HCMV、HSV-Ⅱ、CT、UU and NG were detected. TP and HIV were done with blood sample.
2. A total of 2338 women were screened for cervical lesions. The correlation of HR-HPV genotypes with the histological results was evaluated. Two hundred and thirty six women with CIN2/3 treated by LEEP conization with negative margins confirmed by pathology examination of the surgical specimen were included. The cervical cells for HPV genotype testing were collected before and 6,12,24 months after treatment respectively. HPV genotype and multiple HPV infection were evaluated as possible predictors of residual/recurrent disease.
[Results]
1. The OR of each HR-HPV type for cervical cancer showed that HR-HPV-16 (OR=51.55; 95%CI=28.73-61.86), HR-HPV-18 (OR=52.81; 95%CI=22.84-61.27), HR-HPV-31 (OR= 12.41; 95%CI=10.59-16.68), HR-HPV-53 (OR=2.92; 95%CI= 1.03-8.28), HR-HPV-59 (OR= 13.58; 95%CI=10.76-21.07) and multiple HR-HPV infection (OR=1.11; 95%CI=0.81-3.13). HR-HPV-33, HR-HPV-39, HR-HPV-45 were detected in cervicle cancer only.
2. The crude OR for infections of sexually transmitted pathogenic microbes associated with cervical cancer showed that HCMV (OR=7.106; 95%CI=3.479-14.512), HSV-Ⅱ(OR=32.489; 95%CI=7.514-40.478), CT (OR=12.315; 95%CI= 5.824-26.039), UU (OR=4.564; 95%CI=3.177-6.556), NG (OR=1.662; 95%CI= 0.427-6.467), TP (OR=21.104; 95%CI=7.324-60.816). There was statistically significant difference between cancer group and control group with respect to the pathogen loading dose of HCMV and UU (P＜0.001). There was no statistically significant difference between cancer group and control group with respect to the pathogen loading dose of HSV-Ⅱ, CT and NG (P>0.05)
3. The major risk factors of cervicle cancer included:tuberculosis (OR=4.388; 95%CI=1.846-10.426), sexually transmitted diseases (OR=20.501; 95%CI=7.097-59.226), gravidity, age 16 to 20 of sexual life for the first time, number'of sex partner, HR-HPV,HSV-Ⅱand TP.
4. Analysis by OR revealed that HPV-66,-68, and -CP8304 were associated with CIN 1; HPV-52 was CIN 2/3-associated types.
5. Preoperative infection with either HPV-16 (P=0.007), HPV-18 (P=0.000), HPV-33 (P=0.001) or HPV-45 (P=0.019) was associated with higher rates of residual /recurrent lesions after conization with negative margins. Preoperative infection with multiple HPV types was associated with the highest rate of residual/recurrent lesions compared with infection with single HPV type and HPV negative cases (P=0.005)
[Conclusion]
1. HPV-16,-18,-31,-33,-39,-45,-53, and -59 have more dominant oncogenic risk over others in Fujian. HPV-18 and -16 have the highest oncopotency.
2. Infection of HCMV, HSV-Ⅱ, CT, UU, TP was closely related to the genesis of cervical cancer. Significant combined effects between HPV and infection of HCMV、HSV-Ⅱ、CT、UU、TP was found. Their combination could strengthen the process of the disease and lead to the pathogenesis of cervical cancer.
3. Tuberculosis, sexually transmitted diseases, smoking, gravidity, age 16 to 20 of sexual life for the first time, number of sex partner, HR-HPV, HSV-Ⅱ, TP and so on, were the main risk factors of cervical cancer.
4. The presence of multiple HR-HPV had no increased risk of having cervical carcinoma or precancerous lesion.
5. HPV-66,-68, and -CP83:04 were associated with CIN1; HPV-52 was CIN2/3-associated types in Fujian. The presence of HPV-16,-18,-33 and -45, as well as multiple HPV types pre-LEEP are associated with higher rates of residual/recurrent disease after LEEP.
研究高危型HPV基因型与宫颈癌及宫颈癌前期病变的关联；探讨性传播病原体感染及其DNA负荷量对宫颈癌发生的作用；探讨宫颈癌发病的危险因素,以及性传播病原体感染、行为因素在HPV致癌中的交互作用。[方法]
1、采用病例-对照研究设计,对每位研究对象(308例宫颈癌病例、336例对照)行宫颈癌危险因素调查,取宫颈细胞标本及采集6ml血样。提取宫颈细胞DNA,行HPV DNA、HCMV、HSV-Ⅱ、CT、UU和NG的检测。血清标本用于TP及HIV检测。研究本地区HR-HPV与宫颈癌的关系,性传播病原体感染及其DNA负荷量对宫颈癌发生的作用以及性传播病原体感染、行为因素与HPV致癌的交互作用。
2、对2338位妇女行宫颈三阶梯诊疗程序筛查及HPV DNA检测,以组织病理学检查为金标准,分析HR-HPV基因型与宫颈病变的关系。对因CINⅡ／Ⅲ行LEEP治疗且宫颈切缘阴性的236位患者随访2年。所有患者在LEEP术前,术后6个月,1年和2年取宫颈细胞行HPV DNA检测。探讨HPV基因型与CIN治疗后残留／复发的关系。
[结果]
1、HR-HPV基因型与宫颈癌发生危险性分析：HR-HPV-16(OR=51.55；95%CI=28.73-61.86)、HR-HPV-18(OR=52.81;95%CI=22.84-61.27)、HR-HPV-31(OR=12.41；95%CI=10.59-16.68)、HR-HPV-53(OR=2.92;95%CI=1.03-8.28)、HR-HPV-59(OR=13.58；95%CI=10.76-21.07)、HR-HPV多重感染(OR=1.11；95%CI=0.81-3.13)。HR-HPV-33、HR-HPV-39、HR-HPV-45仅在宫颈癌病例中检出。
2、性传播病原体感染与宫颈癌发生的危险性分析：HCMV(OR=7.106；95%CI=3.479-14.512)；HSV-Ⅱ(OR=32.489；95%CI=7.514-40.478)；CT(OR=12.315;95%CI=5.824-26.039)；UU(OR=4.564；95%CI=3.177-6.556)；NG(OR=1.662；95%CI=0.427-6.467)；TP(OR=21.104；95%CI=7.324-60.816)。HCMV、UU的DNA负荷量在宫颈癌组及对照组,差异有统计学意义(P<0.001)；HSV-Ⅱ、CT、NG的DNA负荷量在宫颈癌组及对照组,差异无统计学意义(P＞0.05)。
3、宫颈癌的危险因素：结核病史(OR=4.388；95%CI=1.846-10.426)、性传播疾病史(OR=20.501;95%CI=7.097-59.226)、怀孕次数多、初次性关系年龄小(16-20岁)、性伴侣数≥3、HR-HPV、HSV-Ⅱ、TP感染。
4、HPV基因型与宫颈癌及癌前期病变的危险性分析：与CINⅠ有关：HPV-66、-68、-CP8304；与CINⅡ／Ⅲ有关：HPV-52。
5、HR-HPV基因型与CIN治疗后残留／复发的关系：治疗前HPV亚型为HR-HPV-16(P=0.007)、HR-HPV-18(P=0.000)、HR-HPV-33(P=0.001)、HR-HPV-45(P=0.019)和HR-HPV多重感染(P=0.005),术后残留／复发率高。
[结论]
1、本地区宫颈癌高危HPV基因型是：HPV-16、-18、-31、-33、-39、-45、-53、-59。感染HPV-18、HPV-16发生宫颈癌的风险最高。
2. HCMV、HSV-Ⅱ、CT、UU、TP感染与宫颈癌发生有关,HCMV、HSV-Ⅱ、CT、UU、TP感染与HPV感染对宫颈癌发生有联合作用,HCMV、TP感染与HPV感染对宫颈癌发生未见交互作用,感染病原体种类数与HPV致癌有联合作用。
3、结核病史、性传播疾病史、怀孕次数多、初次性关系年龄小(16-20岁)、性伴侣数≥3、HR-HPV、HSV-Ⅱ、TP感染是福建地区宫颈癌的主要危险因素。性传播疾病、孕次、性伴侣数在宫颈癌的发生中有联合作用。
4、高危型HPV多重感染无明显增加宫颈癌及癌前病变的风险。
5、感染HPV-66,-68和-CP8304与发生CINⅠ有关,感染HPV-52与发生CINⅡ／Ⅲ有关。CINⅡ／Ⅲ治疗前感染亚型为HPV-16、-18、-33、-45以及HR-HPV多重感染,与治疗后残留／复发的发生有关。
[Objective]
To study the association of HR-HPV genotype with cervical cancer and precancerous lesions, the relation of infections of sexually transmitted pathogenic microbes with cervical cancer, risk factors of cervical cancer in Fujian and the synergistic action of pathogen microbes and behavial factor in etiology of cervicle cancer.
[methods]
1. A case-control design was applied in this study. A total of 308 patients of cervical cancer diagnosed with histology were enrolled and 336 control subjects consisted of patients of hysterectomy with benign lesions. Each participant was scheduled for a face-to-face interview with the structured questionnaire. Cervical cells were obtained and 6 ml blood was collected from all women. Cervical cells DNA was extracted, and HPV DNA、HCMV、HSV-Ⅱ、CT、UU and NG were detected. TP and HIV were done with blood sample.
2. A total of 2338 women were screened for cervical lesions. The correlation of HR-HPV genotypes with the histological results was evaluated. Two hundred and thirty six women with CIN2/3 treated by LEEP conization with negative margins confirmed by pathology examination of the surgical specimen were included. The cervical cells for HPV genotype testing were collected before and 6,12,24 months after treatment respectively. HPV genotype and multiple HPV infection were evaluated as possible predictors of residual/recurrent disease.
[Results]
1. The OR of each HR-HPV type for cervical cancer showed that HR-HPV-16 (OR=51.55; 95%CI=28.73-61.86), HR-HPV-18 (OR=52.81; 95%CI=22.84-61.27), HR-HPV-31 (OR= 12.41; 95%CI=10.59-16.68), HR-HPV-53 (OR=2.92; 95%CI= 1.03-8.28), HR-HPV-59 (OR= 13.58; 95%CI=10.76-21.07) and multiple HR-HPV infection (OR=1.11; 95%CI=0.81-3.13). HR-HPV-33, HR-HPV-39, HR-HPV-45 were detected in cervicle cancer only.
2. The crude OR for infections of sexually transmitted pathogenic microbes associated with cervical cancer showed that HCMV (OR=7.106; 95%CI=3.479-14.512), HSV-Ⅱ(OR=32.489; 95%CI=7.514-40.478), CT (OR=12.315; 95%CI= 5.824-26.039), UU (OR=4.564; 95%CI=3.177-6.556), NG (OR=1.662; 95%CI= 0.427-6.467), TP (OR=21.104; 95%CI=7.324-60.816). There was statistically significant difference between cancer group and control group with respect to the pathogen loading dose of HCMV and UU (P＜0.001). There was no statistically significant difference between cancer group and control group with respect to the pathogen loading dose of HSV-Ⅱ, CT and NG (P>0.05)
3. The major risk factors of cervicle cancer included:tuberculosis (OR=4.388; 95%CI=1.846-10.426), sexually transmitted diseases (OR=20.501; 95%CI=7.097-59.226), gravidity, age 16 to 20 of sexual life for the first time, number'of sex partner, HR-HPV,HSV-Ⅱand TP.
4. Analysis by OR revealed that HPV-66,-68, and -CP8304 were associated with CIN 1; HPV-52 was CIN 2/3-associated types.
5. Preoperative infection with either HPV-16 (P=0.007), HPV-18 (P=0.000), HPV-33 (P=0.001) or HPV-45 (P=0.019) was associated with higher rates of residual /recurrent lesions after conization with negative margins. Preoperative infection with multiple HPV types was associated with the highest rate of residual/recurrent lesions compared with infection with single HPV type and HPV negative cases (P=0.005)
[Conclusion]
1. HPV-16,-18,-31,-33,-39,-45,-53, and -59 have more dominant oncogenic risk over others in Fujian. HPV-18 and -16 have the highest oncopotency.
2. Infection of HCMV, HSV-Ⅱ, CT, UU, TP was closely related to the genesis of cervical cancer. Significant combined effects between HPV and infection of HCMV、HSV-Ⅱ、CT、UU、TP was found. Their combination could strengthen the process of the disease and lead to the pathogenesis of cervical cancer.
3. Tuberculosis, sexually transmitted diseases, smoking, gravidity, age 16 to 20 of sexual life for the first time, number of sex partner, HR-HPV, HSV-Ⅱ, TP and so on, were the main risk factors of cervical cancer.
4. The presence of multiple HR-HPV had no increased risk of having cervical carcinoma or precancerous lesion.
5. HPV-66,-68, and -CP83:04 were associated with CIN1; HPV-52 was CIN2/3-associated types in Fujian. The presence of HPV-16,-18,-33 and -45, as well as multiple HPV types pre-LEEP are associated with higher rates of residual/recurrent disease after LEEP.
引文
1. Food Nutrition and the Prevention of Cancer:a global perspective. First published 1997 by IARC,301-308.
2. Ferlay J, Bray F, Pisani P, et al. Globocan 2000:cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase no.5. Lyons,France:IARC Press,2001.
3. Ghim SJ, Basu PS, Jenson A. Cervical Cancer:Etiology, Pathogenesis, Treatment,and Future Vaccines. Asian Pac J Cancer Prev[J].2002:3 (3):207-214.
4. Parkin DM, BrayF, Ferlay J, Pisani P. Global cancer statistics 2002[J]. CA Cancer J Clin,2005,55(2):74-108.
5.郎景和.迎接子宫颈癌预防的全球挑战与机遇.中华妇产科杂志[J],2002；37(3)：129-131.
6. Cuschieri KS, Cubie HA, Whitley MW, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study[J].J Clin Pathol.2005;58(9):946-950.
7. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues[J]. Nat Rev Cancer 2007;7:11-22.
8. Walboomers J M, Jacobs MV, Manos MM, et al.Human papillomavirus is necessary cause of invasive cervical cancer world-wide[J].J Pathol,1999; 189:12-19.
9. Bosch FX, Manos MM, Munoz N, et al. International biology study on cervical cancer (IBSCC) study grou. p. Prevalence of human papillomavirus in cervical cancer: worldwide perspective [J]. J. Natl. Cancer Inst 1995; 87:796-802.
10. Munoz N, Bosch FX, de Sanjosae S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer[J]. N Engl J Med 2003; 348 (6):518-527.
11. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human Papillomavirus Genotype Distributions:Implications for Vaccination and Cancer Screening in the United States[J]. JNCI Journal of the National Cancer Institute 2009; 101(7):475-487.
12. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide:a meta-analysis[J]. British Journal of Cancer 2003; 88:63-73.
13. An HJ,Cho NH,Lee SY,et al. Correlation of cervical carcinoma and precancerous lesions with human papilliomavirus(HPV) genotypes detected with the HPV DNA chip microarray method[J]. Cancer,2003;97(7):1672-1080.
14. Kirn CJ, Jeong JK, Park M,et al. HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions[J]. Gynecol Oncol,2003; 89(2): 210-217.
15.叶菁,吕卫国,谢幸.人乳头瘤病毒预防性疫苗现状和问题[J].国际妇产科学杂志,2008；35(5)：325-328.
16.乔友林.子宫颈癌预防研究的里程碑[J].基础医学与临床,2006；26(12)：1293-1295.
17. Lee SH, Kang D, Seo ss,et al. Multiple HPV infection in cervical cancer screened by HPV DNA Chip[J]. Cancer Letter,2003,198:187-192.
18. Gargiulo F, Francesco MD, Schreiber C, et al.Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women[J].Virus Res 2007; 125(2):176-82.
19. Cai HB, Ding XH, Chen CC.Prevalence of Single and Multiple Human Papillomavirus Types in Cervical Cancerand Precursor Lesions in Hubei,China[J]. Oncology,2009;76:157-161.
20. Lin H, Ma YY, Moh JS, et al. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan[J]. Gynecol Oncol 2006; 101:40-45
21. Shi JF, Wu RF, Liu ZH, et al. Distribution of human papillomavirus types in Shenzhen women. Zhongguo yi xue ke xue yuan xue bao[J].2006;28:832-836
22. Zhao FH, Forman MR,Belinson J, et al. Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China[J]. Int J Cancer 2006; 118:442-448
23. Wu EQ, Zhang GN, Yu XH, et al. Evaluation of hish-risk Human papillomaviruses type distribution in cervical cancer in Sichuan province of China[J]. BMC Cancer,2008; 8:202-206.
24. Wu Y, Chen Y, Li L, et al. Associations of high-risk HPV types and viral load with cervicalcancer in China[J]. J Clin Virol 2006;35:264-269.
25. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer[J]. Gynecol Oncol 2006;102:54-60.
26. Lo KW, Wong YF, Chan MK, et al. Prevalence of human papillomavirus in cervical cancer:a multicenter study in China[J]. Int J Cancer 2002; 100:327-331.
27. Bao YP, Li N, Smith JS, Qiao YL, et al. Human papillomavirus type distribution in women from Asia:a meta-analysis[J]. Int J Gynecol Cancer,2008; 18:71-79.
28. Pretet JL, Jacquard AC, Carcopino X, et al. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France:EDITH study [J]. Int J Cancer,2008;122:428-432.
29. Ding DC, Hsu HC, Huang PL,et al. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan:an indication of viral oncogenic potential[J]. Eur J Obstet Gynecol Reprod Biol,2008;140(2):245-251.
30. Scheurer ME, Tortolero-Luna G, Guillaud M,et al. Correlation of human papillomavirus type 16 and human papillomavirus type 18 e7 messenjer RNA levels with degree of cervical dysplasia[J]. Cancer Epidemiol Biomarkers Prev,2005; 14(8): 1948-1952.
31. Kurman RJ, Schiffman MH, Lancaster WD, et al. Analysis of individual human papillomavirus types in cervical neoplasia:a possible role for type 18 in rapid progression[J]. Am J Obstet Gynecol,1988;159(2):293-296.
32.李洁,刘宝印,Zur Hausen等.中国妇女宫颈癌组织中人乳头瘤病毒感染及地理分布的调查[J].中华实验和临床病毒学,1996,10：50-55.
33. Huang S, Afonina I, Miller BA, et al. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women[J].Int J Cancer,1997,70 (4): 408-411.
34. Lai CH, Chang CJ, Huang HJ,et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery[J]. J Clin Oncol,2007;25(24):3628-3634.
35. Bulk S, Berkhof J, Bulkmans NW,et al. Preferential risk of HPV 16 for snuamous cell carcinoma and of HPV 18 for adenocarcinoma of the cervix compared to women with normal cytology in the Netherlands [J]. BrJ Cancer,2006;94(1):171-175.
36. de Cremoux P, de la Rochefordiere A, Savignoni A,et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype[J]. Int J Cancer,2009;124(4):778-782.
37. Cuschieri KS, Cubie HA, Whitley MW, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population[J]. Journal of Clinical Pathology,2004,57:68-72.
38. Levi JE, Kleter B, Quint WG, et al. High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil[J]. J Clin Microbiol, 2002,40:3341-3345.
39. Ho GYF., Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia[J]. Natl. Cancer Inst, 1995,87:1365-1371.
40. Trottier HS, Costa MC, Sobrinho JP, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia[J]. Cancer Epidemiol. Biomarkers Prev. 2006,15:1274-1280.
41.陶萍萍,卞美璐,李敏,等.HPV多重感染与宫颈病变关系探讨[J].中国妇产科临床杂志,2006；7(2)；94-97.
42. Cuschieri KS, Cubie HA, Whitley MW, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population[J]. Journal of Clinical Pathology,2004,57:68-72.
43. Parkin DM; Bray F, Ferlay J, et al. Estimating the world burden:globocan 2000[J]. Int J cancer,2001,94:153-156.
44.徐爱强,张桂宁.宫颈癌致病危险因素和病毒学的研究进展[J].预防医学 情报杂志,1992,8(3)：145-148.
45. Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J,et al. Herpes Simplex Virus-2 as a Human Papillomavirus Cofactor in the Etiology of Invasive Cervical Cancer.JNCI Journal of the National Cancer Institute.2002,94 (21): 1604-1613.
46. Finan RR, Musharrafieh U, Almawi WY. Detection of Chlamydia trachomatis and herpes simplex virus type 1 or 2 in cervical samples in human papilloma virus (HPV)-positive and HPV-negative women. Clin Microbiol Infect,2006,12(9): 927-930.
47. Salcedo MM, Silveira GP, Zettler CG. Immunohistochemical expression of p16 and herpes simplex virus type 2 in squamous intraepithelial lesions and cervical cancer. Rev Bras Ginecol Obstet,2008,30(2):61-66.
48.王学东,吴艳乔,鲁斌.我国单纯疱疹Ⅱ型病毒(HSV-2)感染与宫颈癌关系的Meta分析.现代预防医学,2009,36(3)：404-406.
49. Matti Lehtinen, Pentti Koskela, Egil Jellum, Aini Bloigu, Tarja Anttila, Goran Hallmans, et al. Herpes Simplex Virus and Risk of Cervical Cancer:A Longitudinal, Nested Case-Control Study in the Nordic Countries. Am J Epidemiol,2002; 156: 687-692.
50.李连青,朱庆义,郑曙民.聚合酶链反应酶谱分型检测宫颈癌中人乳头瘤病毒和单纯疱疹病毒[J].中华实验和临床病毒学杂志,1999,13：235.
51.庄坚,林莹,李曼红,等.HSV22感染及其PCNA表达与宫颈癌关系的研究[J].汕头大学医学院学报,2001,14：163.
52. Pisani S, Imperi M, Seganti L, Superti F, Tinari A, Bucci M,et al. Effect of HSV-2 infection on the expression of HPV 16 genes in CaSki cells. Int J Immunopathol Pharmacol,2004; 17(1):65-70.
53. Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, et al. Chlamydia trachomatis and invasive cervical cancer:a pooled analysis of the IARC multicentric case-control study. Int J Cancer, September 1,2004; 111(3):431-439.
54. Hakama M, Luostarinen T, Hallmans G, Jellum E, Koskela P, Lehtinen M, et al. Joint effect of HPV 16 with Chlamydia trachomatis and smoking on risk of cervical cancer:antagonism or misclassification (Nordic countries). Cancer Causes Control, October 1,2000; 11(9):783-90.
55. Madeleine MM, Anttila T, Schwartz SM, Saikku P, Leinonen M, Carter JJ,et al.Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors.Int J Cancer, February 1,2007; 120(3): 650-5.
56.王晓红,余平,黎明.宫颈癌与沙眼衣原体感染的相关性研究.实用预防医学,2004；11(1)：46-48.
57.郑曙民,孙立新,武燕,岳丽萍,黄慧,石利香等.宫颈癌与性传播因子的探讨.肿瘤研究与临床,2000；12(1)：21-22.
58.蔡昌金,吴昌辉,梁连辉,储兵,陈述文.HPV-16、沙眼衣原体、生殖道支原体感染与子宫颈癌关系的研究.中国中西医结合皮肤性病学杂志.2005；4(4)：229-231.
59.鲁德银,邓培,孙瑜,王志洁,刘朝奇,郭淑芳.人巨细胞病毒诱发小鼠宫颈癌的实验研究.湖北医科大学学报.1998；16(4)：318-321.
60.王志洁,孙瑜,鲁德银等.人巨细胞病毒对小鼠宫颈的诱癌作用[J].中华实验和临床病毒学杂志,1997,11：24.
61.刘朝奇,韩广州,李昆,司静懿,刘世德,宋国兴.人巨细胞病毒协同人乳头瘤病毒16型诱导宫颈上皮细胞癌变的研究[J].中华病理学杂志,1999；28(1)：24-27.
62.闵洁,林美华.人巨细胞病毒感染与宫颈癌关系的研究[J].同济医科大学学报,2000,29：249-252.
63. Mougin C,Schaal JP,Bassignot A,et al.Detection of human papillomavirus and Human cytomegalovirus in cervical lesions by in situ hybridization using biotinylated probes. Biomed Pharmacother,1991,45:353-357.
64. Chan PKS, Chan MYM, Li WWH, Chan DPC, Cheung JLK, Cheng AF. Association of human β-herpesviruses with the development of cervical cancer: bystanders or cofactors. J Clin Pathol 2001; 54:48-53.
65.周毅.梅毒螺旋体感染与宫颈癌的相关性.中国误诊学杂志,2003,6 (3)：884-885.
66.汤泉,蒋友华.宫颈癌与梅毒螺旋体感染的相关性探讨.肿瘤研究与临床,2004,16(4)：248-249.
67.王艳,马颖,崔玉青.梅毒螺旋体感染与宫颈癌卵巢癌相关性研究.中原医刊,2006,33(7)：59‘.
68. Massad LS, Riester KA,Anastos KM,et al. Prevalence and predictors of squamous cell abnormalities in papanicolaou smears from women infected with HIV-1. Women's interagency HIV Study Group [J]. J Acquir Immune Defic Syndr,1999,21:33.
69. De-Sanjose S,Valls I,Paz-Canadas M,et al. Human papillomavirus and human immunodeficiency virus infections as risk factors for cervix cancer in women prisoners [J].Med Clin (Barc),2000,115:81.
70. Bosch FX, Sanjose S de. The epidemiology of human papillomavirus infection and cervical cancer.Dis Markers,2007; 23(4):213-27.
71.李隆玉,李成信.宫颈癌的预防及普查.中国实用妇科与产科杂志[J],2003,19(3)：151-152.
72.杨玲,皇甫小梅,张思维等.中国20世纪70年代与90年代子宫颈癌死亡率及其变化趋势.中国医学科学院学报[J],2003.25(4).
73.章文华,李楠,吴令英.重视宫颈癌患者年轻化的趋势.浙江肿瘤[J].2000,6(2),112-114.
74.郎景和.子宫颈上皮内瘤变的诊断与治疗.中华妇产科杂志[J],2001,36(5)：261-263.
75. Perez LA. Genital HPV:links to cervical cancer, treatment, and prevention[J].Clin Lab Sci,2001,14(3):183 -186.
76. IARC Technical reports N3. Tobacco smoke and involuntary smoking [M]. IARC Press,2004.
77. Cervical carcinoma and reproductive factor:collaborative reanalysis of individual data on 16,563 women with cervical cancer and 33,542 women without cervical cancer from 25 epidemiological studies[J]. Int J Cancer,2006,119:1108.
78. Cogliano V, Grosse Y, Baab R, et al. Carcinogenicity of combined Oestrogen-progestagen contraceptives and menopausal treatment J]. Lancet Oncol, 2005,6:552.
79. Acharki A. Sahraoui S, Benider A. et al. Cancer of the uterine cervix in young women Aretro spective study of 337 cases [J].Bull Cancer,1997,84(4):373-378.
80. Boyle P, Vecchia C, Walker A, et al. FIGO annual report on the results of treatment in gynecological Cancer [J]. Journal of epidemiology and biostatictcs,2001, 12:7-43.
81.章文华,白萍,吴令英,等.35岁以下妇女宫颈癌[J].中国肿瘤临床与康复,1999,6(6)：39-41.
82. Crowther ME. Is the nature of cervical carcinoma changing in young women? [J]. Obstetrical and Gynecological Survey,1995,50(1):71-82
83.曾转萍,陈凤,刘彬,等.山西省宫颈癌高发区宫颈癌的年龄分布[J].广东药学院学报,2005.2,21(1)：70-72.
84. Shingleton HM,Bell MC, Fremgen A, et al.Is there really difference in survival of women with sequmaous cell carcinoma,adenocarcinoma and adenocarcinoma cell carcinoma of the cervical?[J] Cancer,1995,75:1948-1955.
85.许彩芹,崔金金.年轻宫颈癌153例临床分析[J].中国误诊学杂志,2006,6(4)：675-676.
86.中国妇幼卫生国际合作项目课题协作组.贫困地区农村在婚妇女下生殖道感染现况调查[J].中国妇幼保健,1997,12：176-178.
87. Schiffman M, Castle PE. Human papillomavirus:epidemiology and public healt h[J]. Arch Pat hol Lab Med,2003,128(8):930-934.
88. Munoz N,Franceschi S,Bosetti C,et al. Role of parity and human papillomavirus in cervical cancer:the IRAC multicenter case-control study[J]. Lancet,2002, 359:1093-1101.
89. Hildesheim A,Herrero R,Castle PE,et al. HPV co-factors related to the development of cervical cancer:result s from a population-based study in Costa Rica[J]. Br J Cancer,2001,84 (9):1219-1226.
90. Zhao Fang-hui, Forman MR,Belinson J,et al. Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China[J]. Int J Cancer,2006,118 (2):442-448.
91.王同祥,陶宁,张力,等.宫颈癌危险因素的病例对照研究[J].数理医药学杂志,2004,17(3)：205-206.
92. Womack SD, Chirenje ZM, Gaffikin L, etal.HPV based cervical cancer screening in a population at high risk for HIV infection[J]. Int J Cancer,2000,85:206-210.
93. Gopalkrishna V, Murthy NS, Sharma JK, Roy M, Das DK, Luthra UK, Das BC. Increased human papillomavirus infection with the increasing number of pregnancies in Indian women[J]. Journal of infectious diseases,1995,71(1):254-255.
94. Biernat I, Szczudrawa A, Tomaszcryk J, Ludwin A. HPV infection in pregnantwomen[J]. Ginekol Pol,2003;74(10):1066-1069.
95. Altekruse SF, Lacey JV Jr, Brinton La,et al. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma:Northeastern United States[J]. Am J Obstet Gynecol,2003, 188(3):657-663.
96.曾转萍,陈凤,刘彬,等.山西省阳城县宫颈癌危险因素研究[J].肿瘤防治研究.2004,31(3)：178-181.
97. Cogliano V, Grosse Y, Baab R, et al. Carcinogenicity of combined Oestrogen-progestagen contraceptives and menopausal treatment [J]. Lancet Oncol, 2005,6:552.
98. Madeleine MM,Daling JR,Schwartz SM, et al.Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix[J]. Cancer Epidemiol Biomarkers Prev,2001,1(3):171-177.
99. Tammy SS, Louise B, Robert DB, et al. A Case-Control Study of Risk Factors for Invasive Cervical Cancer among U.S. Women Exposed to Oncogenic Types of Human Papillomavirus. Cancer Epidemiol Biomarkers Prev,2004,13(10):1574-1582.
100. Moreno V, Bosch FX,Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection:the INRC multicentric case-control study[J]. Lancet,2002,359:1085-1092.
101. Brinton LA, Reeves WC, Brenes MM, et al. The male factor in the etiology of cervical cancer among sexually monogamous women [J]. Int J Cancer,1989,44(2): 199-203.
102.刘健,郭邑,张艳开,等.HPV-16、HSV-2、EBV感染及PCNA表达与宫颈癌关系研究[J].大连医科大学学报,2003,25(2)：85-87.
103.郝敏,王静芳.宫颈癌流行病学研究与调查[M].国外医学妇幼保健分册,2005,16(6)：405.
104. Velema J P, Ferrera A, Figueroa M,et al. Burning wood in the kitchen increases the risk of cervical neoplasia in HPV-infected women in honduras[J]. Int J Cancer,2002,97(4):536.
105. Ursin G,Pike MC,Martin S,et al. Reproductive and ot her risk factors for adenocarcinoma of the cervix,results from a population-based case-control study (California, united states) [J].Cancer Causes Control,1996,7(3):391.
106.俞顺章.子宫颈癌危险因素的流行病学研究[J].实用肿瘤杂志,1998,13(3)：138.
107. Shields TS, Brinton LA, Burk RD, et al. A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human pap illomavirus[J]. Cancer Epidemiol Biomarkers Prev,2004,3 (10):1574-1582.
108. IARC Technical reports N3. Tobacco smoke and involuntary smoking [M]. IARC Press,2004.
109. Carcinoma of the cervix and tobacco smoking:Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies[J]. Int J Cancer,2006,118:1482.
110. Castle PE, Wacholder S, Lorinez AT, et al. A Prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women[J]. J Natl Cancer Inst,2002,94(18)1406-1414
111. Wu MT, Lee LH, Ho CK. Lifetime exposure to environmental tobacco smoke and cervical intraepithelial neoplasms among nonsmoking Taiwanese women[J]. Arch Environ Health.2003 Jun;58(61):353-359.
112. Steckley SL, Pickwort h WB, Haverkos HW. Cigarette smoking and cervical cancer:Part Ⅱ:A geographic variability study [J].Biomedicine & Pharmacotherapy,2003,57:78-83.
113. Sierra-Tomes CH,Tring SK, Au WW. Risk contribution of sexual behavior and cigarette smoking to cervical neoplasia[J]. Int J Gynecol Cancer.2003 13 (5): 617-625.
114. zur Hausen H. Papillomaviruses and cancer:from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
115. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. Clin. Pathol 2002;55:244-265.
116. Burd EM. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev 2003;16:1-17.
117. Cuzick JA, Szarewski H, Cubie G, et al. Management of women who test positive for high-risk types of human papillomavirus:the HART study. Lancet 2003;362:1871-1876.
118. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med 1992;327:1272-1278.
119. Fehrmann F, Laimins LA. Human papillomaviruses targeting differentiating epithelial cells for malignant transformation. Oncogene 2003;22:5201-7.
120. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369(9580):2161-2170.
121. Shefer A, Markowitz L, Deeks S, et al. Early experience with human papillomavirus vaccine introduction in the United States, Canada, and Australia. Vaccine 2008; 26(S10):K68-K75.
122. Kalof AN, Evans MF, Simmons-Arnold L, Beatty BG, Cooper K. p16INK4A immunoexpression and HPV in situ hybridization signal patterns:potential markers of high-grade cervical intraepithelial neoplasia. Am. J. Surg. Pathol 2005;29:674-679.
123. Wright TC. Cervical cancer screening in the 21st century: is it time to retire the PAP smear? Clin Obst Gynecol 2007;50:313-23.
124. Villa L, Denny L. Methods for detection of HPV infection and its clinical utility. Int J Gynecol Obstet 2006;94:S71-80.
125. Gaelle A.V. Boulet, Caroline A.J. Horvath, Sarah Berghmans and Johannes Bogers. Human Papillomavirus in Cervical Cancer Screening:Important Role as Biomarker. Cancer Epidemiol Biomarkers Prev 2008;17(4):810-817.
126. Markowitz LE, Unger ER, Mona Saraiya. Primary and Secondary Prevention of Cervical Cancer-Opportunities and Challenges. J Natl Cancer Inst 2009;101(7):439-440.
127. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, ChangChien CC. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan.Gynecol Oncol 2006; 101(1):40-5.
128. Lin M, Yang LY, Li LJ, Wu JR, Peng YP, Luo ZY. Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust New Zeal J Obstet Gynaecol 2008; 48:189-194.
129. Ding DC, Hsu HC, Huang RL, et al.Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan:an indication of viral oncogenic potential. Eur J Obstet Gynecol Reprod Biol 2008; 140(2):245-51.
130. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3:a retrospective cohort study. Lancet Oncol 2008;9:425-434.
131. Pinto AP, Crum CP. Natural history of cervical neoplasia:defining progression and its consequence. Clin Obstet Gynecol 2000;43:352-362.
132. Prendiville W, Cullimore J, Norman S. Large loop excision of the transformation zone (LLETZ):a new method of management for women with cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1989;96:1054-1060.
133. Lindeque BG. Management of cervical premalignant lesions. Best Pract Res Clin Obstet Gynaecol 2005; 19:545-561.
134. Paraskevaidis E, Lolis ED, Koliopoulos G, Alamanos Y, Fotiou S, Kitchener HC. Cervical intraepithelial neoplasia outcomes after large loop excision with clear margins. Obstet Gynecol 2000;95:828-31.
135. Kyehyun Nam, Sooho Chung, Jeongsig Kim, Seob Jeon, Donghan Bae. Factors associated with HPV persistence after conization in patients with negative margins. J Gynecol Oncol 2009; 20(2):91-95.
136. Paraskevaidis E, Jandial L, Mann EMF, Fisher PM, Kitchener HC. Pattern of treatment failure following laser for cervical intraepithelial neoplasia:Implications for follow-up protocol. Obstet Gynecol 1991;78:80-3.
137. Cecchini S, Visioli CB, Zappa M, Ciatto S. Recurrence after treatment by loop electrosurgical excision procedure (LEEP) of high-grade cervical intraepithelial neoplasia.Tumori 2002; 88(6):478-80.
138. Ghaem-Maghami S, Sagi S, Majeed G, Soutter WP. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure:a meta-analysis. Lancet Oncol 2007;8:985-993.
139. Jakus S, Edmonds P, Dunton C, King SA. Margin status and excision of cervical intraepithelial neoplasia:a review. Obstet Gynecol Surv 2000;55:520-7.
140. Costa S, De Simone P, Venturoli S, Cricca M, Zerbini ML, Musiani M, et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol Oncol 2003;90:358-65.
141. Houfflin Debarge V, Collinet P, Vinatier D, Ego A, Dewilde A, Boman F, et al. Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. Gynecol Oncol 2003;90:587-92.
142. Brockmeyer AD, Wright JD, Gao F, Powell MA. Persistent and recurrent cervical dysplasia after loop electrosurgical excision procedure. Am J Obstet Gynecol 2005;192:1379-81.
143. Paraskevaidis E,Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN:a systematic review of the literature. Cancer Treat Rev 2004;30:205-11,
144. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, et al. HPV testing and monitoring of women after treatment of CIN 3:review of the literature and meta-analysis. Obstet Gynecol Surv 2004;59:543-53.
145. Aerssens A, Claeys P, Beerens E, Garcia A, Weyers S, Van Renterghem L, et al. Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia.Cytopathology 2009; 20(1):27-35.
146. Sarian LO, Derchain SF, Andrade LA, Tambascia J, Morais SS, Syrjanen KJ. HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2004; 94(1):181-6.
147. Alonso I, Tome A, Puig-Tintore LM, Esteve R, Quinto L, Campo E, et al. Pre-and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006;103:631-636.
148. Bae JH, Kim CJ, Park TC, Namkoong SE, Park JS. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. Int J Gynecol Cancer 2007;17:1271-1277.
149. Sarian LO, Derchain SF, Pitta Dda R, Morais SS, Rabelo-Santos SH. Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ). J Clin Virol 2004;31:270-274.
150. Soutter WP, de Barros Lopes A, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997;349:978-980.
151. Song SH, Lee JK, Oh MJ, Hur JY, Na JY, Park YK, et al. Persistent HPV infection after conization in patients with negative margins. Gynecol Oncol 2006;101:418-422.
152. Park JY, Lee KH, Dong SM, Kang S, Park SY, Seo SS. The association of pre-conization high-risk HPV load and the persistence of HPV infection and persistence/recurrence of cervical intraepithelial neoplasia after conization. Gynecol Oncol 2008;108:549-554.
153. Rousseau MC, Abrahamowicz M, Villa LL, Costa MC, Rohan T E, Franco EL.Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2003;12:1029-37.
154. Gargiulo F, Francesco MD, Schreiber C, Ciravolo G, Salinaro F, Valloncini B,et al. Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women.Virus Res 2007; 125(2):176-82.
155. Bachtiary B, Obermair A, Dreier B, Birner P, Breitenecker G, Knocke T H, et al. Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. Int. J. Cancer 2002; 102,237-243.
156. Munagala R, Dona MG, Rai SN, Jenson AB, Bala N, Ghim SJ, et al. Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response. Int J Oncol 2009; 34(1):263-71.
1. Parkin DM, BrayF, Ferlay J, Pisani P. Global cancer statistics 2002[J]. CA Cancer J Clin,2005,55(2):74-108.
2.郎景和.迎接子宫颈癌预防的全球挑战与机遇.中华妇产科杂志[J],2002；37(3)：129-131.
3.Munoz N, Bosch Fx, Sanjose S, et al. Epidemiologie classification of human papilloma virus types associated with cervical cancer[J]. N Engl J Med,2003,348:8.
4. Bosch FX, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer:a world perspective [J]. J of the Natinal Cancer Last,1995,87:796-802.
5. Sawe EI, Kjaer sk, Worm Am, et al. Risk factor for genital HPV DNA in men resemb ler thosefound in women:a study of male attendees at a Danish STD clinic[J]:Sex Transan Infect,2002,78:5.
6. Vddman T, Liu X, Yuan H. et al. Human papillomavirus E6 and Myc proteins. associate in vivo and bind to and cooperatively activte the telomerase reverse transcriptase promoter[J]. Proc Natl Acad Sci USA,2003,100(14):8211.
7. Gewin L, Galloway DA. E Box-dependent activation of telomerase by human papillomavirus type16 E6 does not require induction of c-myc[J]. J Virol,2001, 75(15):7198-7201.
8. Pao CC, ISeng CJ, Lm CY, et al. Diferent expression of telomerase activity in human cervical intraepithelial neoplasia lesions[J]. J Clin Oncol,1997,15(5):19-32.
9. Won J, Yin J, Kim TK. Oppllsing regulatory roles of E2F in human telomerase reverse teanscriptase(hTERT)gene expression in human tumor and nomal somatic ceils[J]. J FASEB,2002,16(14):1943-1945.
10. Boldrini L, Faviana P, Gisfredi S, et al. Regulation of telomerase its hTERT messenger in colorectal cancer[J]. Oncol Rep,2004,11(2):395-400.
11. Crish JF, Bone F, Balasubramainian S, et al. Suprabasal expression on the human papillomavirus type 16 onconproteins in mouse epidermis alters expression of cell cycle regulatory proteins. Carcinogenesis,2000,21(5):1031-1037
12. Kang YH, Lee KA, Ryu CJ, et al. Mitomycin C induces apoptois via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells[J]. Cancer Lett,2006,237(1):33-34.
13. Hubert P, Caberg JH, Gilles C, et al. E-cadherin-dependent adhesion of dendritic and Langerhans cells to keratinocytes is dfective in cervical human papillomavirus-associated (pre)neoplastic lesions [J]. J Pathol,2005,206(3): 346-355.
14. Clavel C, Masure M, Le vert M, et al. Human papillomavirus detection by the hybrid capture Ⅱ assay:a reliable test to select women with normal cervical smears at risk for developing cervieal lesions. Diagn Mol Pathol,2000,9 (3):145-150.
15.陶萍萍,卞美潞,欧华等.导流杂交基因芯片技术在人乳头状瘤病毒检测中 应用的研究[J].中华妇产科杂志,2006,41(1)：43-47.
16. Nardeli-Haefliger D, WirthnerD, Schiler JT, etal. Specific antibody levels at the cervix during the menstrual cycle of women vaccined with human papilomavirus 16 virus-like particles. Natl Cancer Inst.2003.95:1128-1137.
17.Koutsky LA, Ault KA, W heeler CM, et al. Proof of Principle Study Investigators:A controled trial of a human papillomavirus type 16 vaccine. N Engl J Med,2002,347(21):1645 - 1651.
18. Auh KA, Giuliano AR, Edwards RP, et al. A phasel study to evaluate a human papilomavirus(HPV)type 18 L1 VLP vaccine. Vaccine,2004.22(23-24):3004-3007.
19. Vilia LL. Costa RL. Petta CA. et al. Prophylactic quadrivalent human papillomavirus(types 6, 11,16and18)L1 virus-like particle vaccine in young women:a randomized double-blind placebo-controled muticentre phase Ⅱ efficacy trial. Lancet Oncol.2005,6:256-257.
20. Harper DM, Franco EL, W heeler C, et al. Eficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 an d 18 in young women:a randomised controled trial. Lancet,2004,364:1731-1732.
21. Muler M, Zhou J, Reed TD, et al. Chimeric papillomavirus-like particles. Virology.1997,234:93-111.
22. Moniz M, Ling M, Hung CF, et al. HPV DNA vaccines. Front Biosci,2003,8: 55-68.
23. Brinkman JA, Caffrey AS, Muderspach LI, et al. The impact of antiHPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol,2005,26(2):129-142.
24. Harper DM, Fran coEL, W heeler CM, et al. Sustained efficacy upto 4.5 years of a bivalent L1 virus-like particle vaccine against human papilomavirus types 16 and 18:follow-up from a randomized controled trial. Lancet.2006,367:1247-1255.
2. Ferlay J, Bray F, Pisani P, et al. Globocan 2000:cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase no.5. Lyons,France:IARC Press,2001.
3. Ghim SJ, Basu PS, Jenson A. Cervical Cancer:Etiology, Pathogenesis, Treatment,and Future Vaccines. Asian Pac J Cancer Prev[J].2002:3 (3):207-214.
4. Parkin DM, BrayF, Ferlay J, Pisani P. Global cancer statistics 2002[J]. CA Cancer J Clin,2005,55(2):74-108.
5.郎景和.迎接子宫颈癌预防的全球挑战与机遇.中华妇产科杂志[J],2002；37(3)：129-131.
6. Cuschieri KS, Cubie HA, Whitley MW, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study[J].J Clin Pathol.2005;58(9):946-950.
7. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues[J]. Nat Rev Cancer 2007;7:11-22.
8. Walboomers J M, Jacobs MV, Manos MM, et al.Human papillomavirus is necessary cause of invasive cervical cancer world-wide[J].J Pathol,1999; 189:12-19.
9. Bosch FX, Manos MM, Munoz N, et al. International biology study on cervical cancer (IBSCC) study grou. p. Prevalence of human papillomavirus in cervical cancer: worldwide perspective [J]. J. Natl. Cancer Inst 1995; 87:796-802.
10. Munoz N, Bosch FX, de Sanjosae S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer[J]. N Engl J Med 2003; 348 (6):518-527.
11. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human Papillomavirus Genotype Distributions:Implications for Vaccination and Cancer Screening in the United States[J]. JNCI Journal of the National Cancer Institute 2009; 101(7):475-487.
12. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide:a meta-analysis[J]. British Journal of Cancer 2003; 88:63-73.
13. An HJ,Cho NH,Lee SY,et al. Correlation of cervical carcinoma and precancerous lesions with human papilliomavirus(HPV) genotypes detected with the HPV DNA chip microarray method[J]. Cancer,2003;97(7):1672-1080.
14. Kirn CJ, Jeong JK, Park M,et al. HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions[J]. Gynecol Oncol,2003; 89(2): 210-217.
15.叶菁,吕卫国,谢幸.人乳头瘤病毒预防性疫苗现状和问题[J].国际妇产科学杂志,2008；35(5)：325-328.
16.乔友林.子宫颈癌预防研究的里程碑[J].基础医学与临床,2006；26(12)：1293-1295.
17. Lee SH, Kang D, Seo ss,et al. Multiple HPV infection in cervical cancer screened by HPV DNA Chip[J]. Cancer Letter,2003,198:187-192.
18. Gargiulo F, Francesco MD, Schreiber C, et al.Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women[J].Virus Res 2007; 125(2):176-82.
19. Cai HB, Ding XH, Chen CC.Prevalence of Single and Multiple Human Papillomavirus Types in Cervical Cancerand Precursor Lesions in Hubei,China[J]. Oncology,2009;76:157-161.
20. Lin H, Ma YY, Moh JS, et al. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan[J]. Gynecol Oncol 2006; 101:40-45
21. Shi JF, Wu RF, Liu ZH, et al. Distribution of human papillomavirus types in Shenzhen women. Zhongguo yi xue ke xue yuan xue bao[J].2006;28:832-836
22. Zhao FH, Forman MR,Belinson J, et al. Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China[J]. Int J Cancer 2006; 118:442-448
23. Wu EQ, Zhang GN, Yu XH, et al. Evaluation of hish-risk Human papillomaviruses type distribution in cervical cancer in Sichuan province of China[J]. BMC Cancer,2008; 8:202-206.
24. Wu Y, Chen Y, Li L, et al. Associations of high-risk HPV types and viral load with cervicalcancer in China[J]. J Clin Virol 2006;35:264-269.
25. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer[J]. Gynecol Oncol 2006;102:54-60.
26. Lo KW, Wong YF, Chan MK, et al. Prevalence of human papillomavirus in cervical cancer:a multicenter study in China[J]. Int J Cancer 2002; 100:327-331.
27. Bao YP, Li N, Smith JS, Qiao YL, et al. Human papillomavirus type distribution in women from Asia:a meta-analysis[J]. Int J Gynecol Cancer,2008; 18:71-79.
28. Pretet JL, Jacquard AC, Carcopino X, et al. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France:EDITH study [J]. Int J Cancer,2008;122:428-432.
29. Ding DC, Hsu HC, Huang PL,et al. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan:an indication of viral oncogenic potential[J]. Eur J Obstet Gynecol Reprod Biol,2008;140(2):245-251.
30. Scheurer ME, Tortolero-Luna G, Guillaud M,et al. Correlation of human papillomavirus type 16 and human papillomavirus type 18 e7 messenjer RNA levels with degree of cervical dysplasia[J]. Cancer Epidemiol Biomarkers Prev,2005; 14(8): 1948-1952.
31. Kurman RJ, Schiffman MH, Lancaster WD, et al. Analysis of individual human papillomavirus types in cervical neoplasia:a possible role for type 18 in rapid progression[J]. Am J Obstet Gynecol,1988;159(2):293-296.
32.李洁,刘宝印,Zur Hausen等.中国妇女宫颈癌组织中人乳头瘤病毒感染及地理分布的调查[J].中华实验和临床病毒学,1996,10：50-55.
33. Huang S, Afonina I, Miller BA, et al. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women[J].Int J Cancer,1997,70 (4): 408-411.
34. Lai CH, Chang CJ, Huang HJ,et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery[J]. J Clin Oncol,2007;25(24):3628-3634.
35. Bulk S, Berkhof J, Bulkmans NW,et al. Preferential risk of HPV 16 for snuamous cell carcinoma and of HPV 18 for adenocarcinoma of the cervix compared to women with normal cytology in the Netherlands [J]. BrJ Cancer,2006;94(1):171-175.
36. de Cremoux P, de la Rochefordiere A, Savignoni A,et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype[J]. Int J Cancer,2009;124(4):778-782.
37. Cuschieri KS, Cubie HA, Whitley MW, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population[J]. Journal of Clinical Pathology,2004,57:68-72.
38. Levi JE, Kleter B, Quint WG, et al. High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil[J]. J Clin Microbiol, 2002,40:3341-3345.
39. Ho GYF., Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia[J]. Natl. Cancer Inst, 1995,87:1365-1371.
40. Trottier HS, Costa MC, Sobrinho JP, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia[J]. Cancer Epidemiol. Biomarkers Prev. 2006,15:1274-1280.
41.陶萍萍,卞美璐,李敏,等.HPV多重感染与宫颈病变关系探讨[J].中国妇产科临床杂志,2006；7(2)；94-97.
42. Cuschieri KS, Cubie HA, Whitley MW, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population[J]. Journal of Clinical Pathology,2004,57:68-72.
43. Parkin DM; Bray F, Ferlay J, et al. Estimating the world burden:globocan 2000[J]. Int J cancer,2001,94:153-156.
44.徐爱强,张桂宁.宫颈癌致病危险因素和病毒学的研究进展[J].预防医学 情报杂志,1992,8(3)：145-148.
45. Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J,et al. Herpes Simplex Virus-2 as a Human Papillomavirus Cofactor in the Etiology of Invasive Cervical Cancer.JNCI Journal of the National Cancer Institute.2002,94 (21): 1604-1613.
46. Finan RR, Musharrafieh U, Almawi WY. Detection of Chlamydia trachomatis and herpes simplex virus type 1 or 2 in cervical samples in human papilloma virus (HPV)-positive and HPV-negative women. Clin Microbiol Infect,2006,12(9): 927-930.
47. Salcedo MM, Silveira GP, Zettler CG. Immunohistochemical expression of p16 and herpes simplex virus type 2 in squamous intraepithelial lesions and cervical cancer. Rev Bras Ginecol Obstet,2008,30(2):61-66.
48.王学东,吴艳乔,鲁斌.我国单纯疱疹Ⅱ型病毒(HSV-2)感染与宫颈癌关系的Meta分析.现代预防医学,2009,36(3)：404-406.
49. Matti Lehtinen, Pentti Koskela, Egil Jellum, Aini Bloigu, Tarja Anttila, Goran Hallmans, et al. Herpes Simplex Virus and Risk of Cervical Cancer:A Longitudinal, Nested Case-Control Study in the Nordic Countries. Am J Epidemiol,2002; 156: 687-692.
50.李连青,朱庆义,郑曙民.聚合酶链反应酶谱分型检测宫颈癌中人乳头瘤病毒和单纯疱疹病毒[J].中华实验和临床病毒学杂志,1999,13：235.
51.庄坚,林莹,李曼红,等.HSV22感染及其PCNA表达与宫颈癌关系的研究[J].汕头大学医学院学报,2001,14：163.
52. Pisani S, Imperi M, Seganti L, Superti F, Tinari A, Bucci M,et al. Effect of HSV-2 infection on the expression of HPV 16 genes in CaSki cells. Int J Immunopathol Pharmacol,2004; 17(1):65-70.
53. Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, et al. Chlamydia trachomatis and invasive cervical cancer:a pooled analysis of the IARC multicentric case-control study. Int J Cancer, September 1,2004; 111(3):431-439.
54. Hakama M, Luostarinen T, Hallmans G, Jellum E, Koskela P, Lehtinen M, et al. Joint effect of HPV 16 with Chlamydia trachomatis and smoking on risk of cervical cancer:antagonism or misclassification (Nordic countries). Cancer Causes Control, October 1,2000; 11(9):783-90.
55. Madeleine MM, Anttila T, Schwartz SM, Saikku P, Leinonen M, Carter JJ,et al.Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors.Int J Cancer, February 1,2007; 120(3): 650-5.
56.王晓红,余平,黎明.宫颈癌与沙眼衣原体感染的相关性研究.实用预防医学,2004；11(1)：46-48.
57.郑曙民,孙立新,武燕,岳丽萍,黄慧,石利香等.宫颈癌与性传播因子的探讨.肿瘤研究与临床,2000；12(1)：21-22.
58.蔡昌金,吴昌辉,梁连辉,储兵,陈述文.HPV-16、沙眼衣原体、生殖道支原体感染与子宫颈癌关系的研究.中国中西医结合皮肤性病学杂志.2005；4(4)：229-231.
59.鲁德银,邓培,孙瑜,王志洁,刘朝奇,郭淑芳.人巨细胞病毒诱发小鼠宫颈癌的实验研究.湖北医科大学学报.1998；16(4)：318-321.
60.王志洁,孙瑜,鲁德银等.人巨细胞病毒对小鼠宫颈的诱癌作用[J].中华实验和临床病毒学杂志,1997,11：24.
61.刘朝奇,韩广州,李昆,司静懿,刘世德,宋国兴.人巨细胞病毒协同人乳头瘤病毒16型诱导宫颈上皮细胞癌变的研究[J].中华病理学杂志,1999；28(1)：24-27.
62.闵洁,林美华.人巨细胞病毒感染与宫颈癌关系的研究[J].同济医科大学学报,2000,29：249-252.
63. Mougin C,Schaal JP,Bassignot A,et al.Detection of human papillomavirus and Human cytomegalovirus in cervical lesions by in situ hybridization using biotinylated probes. Biomed Pharmacother,1991,45:353-357.
64. Chan PKS, Chan MYM, Li WWH, Chan DPC, Cheung JLK, Cheng AF. Association of human β-herpesviruses with the development of cervical cancer: bystanders or cofactors. J Clin Pathol 2001; 54:48-53.
65.周毅.梅毒螺旋体感染与宫颈癌的相关性.中国误诊学杂志,2003,6 (3)：884-885.
66.汤泉,蒋友华.宫颈癌与梅毒螺旋体感染的相关性探讨.肿瘤研究与临床,2004,16(4)：248-249.
67.王艳,马颖,崔玉青.梅毒螺旋体感染与宫颈癌卵巢癌相关性研究.中原医刊,2006,33(7)：59‘.
68. Massad LS, Riester KA,Anastos KM,et al. Prevalence and predictors of squamous cell abnormalities in papanicolaou smears from women infected with HIV-1. Women's interagency HIV Study Group [J]. J Acquir Immune Defic Syndr,1999,21:33.
69. De-Sanjose S,Valls I,Paz-Canadas M,et al. Human papillomavirus and human immunodeficiency virus infections as risk factors for cervix cancer in women prisoners [J].Med Clin (Barc),2000,115:81.
70. Bosch FX, Sanjose S de. The epidemiology of human papillomavirus infection and cervical cancer.Dis Markers,2007; 23(4):213-27.
71.李隆玉,李成信.宫颈癌的预防及普查.中国实用妇科与产科杂志[J],2003,19(3)：151-152.
72.杨玲,皇甫小梅,张思维等.中国20世纪70年代与90年代子宫颈癌死亡率及其变化趋势.中国医学科学院学报[J],2003.25(4).
73.章文华,李楠,吴令英.重视宫颈癌患者年轻化的趋势.浙江肿瘤[J].2000,6(2),112-114.
74.郎景和.子宫颈上皮内瘤变的诊断与治疗.中华妇产科杂志[J],2001,36(5)：261-263.
75. Perez LA. Genital HPV:links to cervical cancer, treatment, and prevention[J].Clin Lab Sci,2001,14(3):183 -186.
76. IARC Technical reports N3. Tobacco smoke and involuntary smoking [M]. IARC Press,2004.
77. Cervical carcinoma and reproductive factor:collaborative reanalysis of individual data on 16,563 women with cervical cancer and 33,542 women without cervical cancer from 25 epidemiological studies[J]. Int J Cancer,2006,119:1108.
78. Cogliano V, Grosse Y, Baab R, et al. Carcinogenicity of combined Oestrogen-progestagen contraceptives and menopausal treatment J]. Lancet Oncol, 2005,6:552.
79. Acharki A. Sahraoui S, Benider A. et al. Cancer of the uterine cervix in young women Aretro spective study of 337 cases [J].Bull Cancer,1997,84(4):373-378.
80. Boyle P, Vecchia C, Walker A, et al. FIGO annual report on the results of treatment in gynecological Cancer [J]. Journal of epidemiology and biostatictcs,2001, 12:7-43.
81.章文华,白萍,吴令英,等.35岁以下妇女宫颈癌[J].中国肿瘤临床与康复,1999,6(6)：39-41.
82. Crowther ME. Is the nature of cervical carcinoma changing in young women? [J]. Obstetrical and Gynecological Survey,1995,50(1):71-82
83.曾转萍,陈凤,刘彬,等.山西省宫颈癌高发区宫颈癌的年龄分布[J].广东药学院学报,2005.2,21(1)：70-72.
84. Shingleton HM,Bell MC, Fremgen A, et al.Is there really difference in survival of women with sequmaous cell carcinoma,adenocarcinoma and adenocarcinoma cell carcinoma of the cervical?[J] Cancer,1995,75:1948-1955.
85.许彩芹,崔金金.年轻宫颈癌153例临床分析[J].中国误诊学杂志,2006,6(4)：675-676.
86.中国妇幼卫生国际合作项目课题协作组.贫困地区农村在婚妇女下生殖道感染现况调查[J].中国妇幼保健,1997,12：176-178.
87. Schiffman M, Castle PE. Human papillomavirus:epidemiology and public healt h[J]. Arch Pat hol Lab Med,2003,128(8):930-934.
88. Munoz N,Franceschi S,Bosetti C,et al. Role of parity and human papillomavirus in cervical cancer:the IRAC multicenter case-control study[J]. Lancet,2002, 359:1093-1101.
89. Hildesheim A,Herrero R,Castle PE,et al. HPV co-factors related to the development of cervical cancer:result s from a population-based study in Costa Rica[J]. Br J Cancer,2001,84 (9):1219-1226.
90. Zhao Fang-hui, Forman MR,Belinson J,et al. Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China[J]. Int J Cancer,2006,118 (2):442-448.
91.王同祥,陶宁,张力,等.宫颈癌危险因素的病例对照研究[J].数理医药学杂志,2004,17(3)：205-206.
92. Womack SD, Chirenje ZM, Gaffikin L, etal.HPV based cervical cancer screening in a population at high risk for HIV infection[J]. Int J Cancer,2000,85:206-210.
93. Gopalkrishna V, Murthy NS, Sharma JK, Roy M, Das DK, Luthra UK, Das BC. Increased human papillomavirus infection with the increasing number of pregnancies in Indian women[J]. Journal of infectious diseases,1995,71(1):254-255.
94. Biernat I, Szczudrawa A, Tomaszcryk J, Ludwin A. HPV infection in pregnantwomen[J]. Ginekol Pol,2003;74(10):1066-1069.
95. Altekruse SF, Lacey JV Jr, Brinton La,et al. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma:Northeastern United States[J]. Am J Obstet Gynecol,2003, 188(3):657-663.
96.曾转萍,陈凤,刘彬,等.山西省阳城县宫颈癌危险因素研究[J].肿瘤防治研究.2004,31(3)：178-181.
97. Cogliano V, Grosse Y, Baab R, et al. Carcinogenicity of combined Oestrogen-progestagen contraceptives and menopausal treatment [J]. Lancet Oncol, 2005,6:552.
98. Madeleine MM,Daling JR,Schwartz SM, et al.Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix[J]. Cancer Epidemiol Biomarkers Prev,2001,1(3):171-177.
99. Tammy SS, Louise B, Robert DB, et al. A Case-Control Study of Risk Factors for Invasive Cervical Cancer among U.S. Women Exposed to Oncogenic Types of Human Papillomavirus. Cancer Epidemiol Biomarkers Prev,2004,13(10):1574-1582.
100. Moreno V, Bosch FX,Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection:the INRC multicentric case-control study[J]. Lancet,2002,359:1085-1092.
101. Brinton LA, Reeves WC, Brenes MM, et al. The male factor in the etiology of cervical cancer among sexually monogamous women [J]. Int J Cancer,1989,44(2): 199-203.
102.刘健,郭邑,张艳开,等.HPV-16、HSV-2、EBV感染及PCNA表达与宫颈癌关系研究[J].大连医科大学学报,2003,25(2)：85-87.
103.郝敏,王静芳.宫颈癌流行病学研究与调查[M].国外医学妇幼保健分册,2005,16(6)：405.
104. Velema J P, Ferrera A, Figueroa M,et al. Burning wood in the kitchen increases the risk of cervical neoplasia in HPV-infected women in honduras[J]. Int J Cancer,2002,97(4):536.
105. Ursin G,Pike MC,Martin S,et al. Reproductive and ot her risk factors for adenocarcinoma of the cervix,results from a population-based case-control study (California, united states) [J].Cancer Causes Control,1996,7(3):391.
106.俞顺章.子宫颈癌危险因素的流行病学研究[J].实用肿瘤杂志,1998,13(3)：138.
107. Shields TS, Brinton LA, Burk RD, et al. A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human pap illomavirus[J]. Cancer Epidemiol Biomarkers Prev,2004,3 (10):1574-1582.
108. IARC Technical reports N3. Tobacco smoke and involuntary smoking [M]. IARC Press,2004.
109. Carcinoma of the cervix and tobacco smoking:Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies[J]. Int J Cancer,2006,118:1482.
110. Castle PE, Wacholder S, Lorinez AT, et al. A Prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women[J]. J Natl Cancer Inst,2002,94(18)1406-1414
111. Wu MT, Lee LH, Ho CK. Lifetime exposure to environmental tobacco smoke and cervical intraepithelial neoplasms among nonsmoking Taiwanese women[J]. Arch Environ Health.2003 Jun;58(61):353-359.
112. Steckley SL, Pickwort h WB, Haverkos HW. Cigarette smoking and cervical cancer:Part Ⅱ:A geographic variability study [J].Biomedicine & Pharmacotherapy,2003,57:78-83.
113. Sierra-Tomes CH,Tring SK, Au WW. Risk contribution of sexual behavior and cigarette smoking to cervical neoplasia[J]. Int J Gynecol Cancer.2003 13 (5): 617-625.
114. zur Hausen H. Papillomaviruses and cancer:from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
115. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. Clin. Pathol 2002;55:244-265.
116. Burd EM. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev 2003;16:1-17.
117. Cuzick JA, Szarewski H, Cubie G, et al. Management of women who test positive for high-risk types of human papillomavirus:the HART study. Lancet 2003;362:1871-1876.
118. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med 1992;327:1272-1278.
119. Fehrmann F, Laimins LA. Human papillomaviruses targeting differentiating epithelial cells for malignant transformation. Oncogene 2003;22:5201-7.
120. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369(9580):2161-2170.
121. Shefer A, Markowitz L, Deeks S, et al. Early experience with human papillomavirus vaccine introduction in the United States, Canada, and Australia. Vaccine 2008; 26(S10):K68-K75.
122. Kalof AN, Evans MF, Simmons-Arnold L, Beatty BG, Cooper K. p16INK4A immunoexpression and HPV in situ hybridization signal patterns:potential markers of high-grade cervical intraepithelial neoplasia. Am. J. Surg. Pathol 2005;29:674-679.
123. Wright TC. Cervical cancer screening in the 21st century: is it time to retire the PAP smear? Clin Obst Gynecol 2007;50:313-23.
124. Villa L, Denny L. Methods for detection of HPV infection and its clinical utility. Int J Gynecol Obstet 2006;94:S71-80.
125. Gaelle A.V. Boulet, Caroline A.J. Horvath, Sarah Berghmans and Johannes Bogers. Human Papillomavirus in Cervical Cancer Screening:Important Role as Biomarker. Cancer Epidemiol Biomarkers Prev 2008;17(4):810-817.
126. Markowitz LE, Unger ER, Mona Saraiya. Primary and Secondary Prevention of Cervical Cancer-Opportunities and Challenges. J Natl Cancer Inst 2009;101(7):439-440.
127. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, ChangChien CC. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan.Gynecol Oncol 2006; 101(1):40-5.
128. Lin M, Yang LY, Li LJ, Wu JR, Peng YP, Luo ZY. Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust New Zeal J Obstet Gynaecol 2008; 48:189-194.
129. Ding DC, Hsu HC, Huang RL, et al.Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan:an indication of viral oncogenic potential. Eur J Obstet Gynecol Reprod Biol 2008; 140(2):245-51.
130. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3:a retrospective cohort study. Lancet Oncol 2008;9:425-434.
131. Pinto AP, Crum CP. Natural history of cervical neoplasia:defining progression and its consequence. Clin Obstet Gynecol 2000;43:352-362.
132. Prendiville W, Cullimore J, Norman S. Large loop excision of the transformation zone (LLETZ):a new method of management for women with cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1989;96:1054-1060.
133. Lindeque BG. Management of cervical premalignant lesions. Best Pract Res Clin Obstet Gynaecol 2005; 19:545-561.
134. Paraskevaidis E, Lolis ED, Koliopoulos G, Alamanos Y, Fotiou S, Kitchener HC. Cervical intraepithelial neoplasia outcomes after large loop excision with clear margins. Obstet Gynecol 2000;95:828-31.
135. Kyehyun Nam, Sooho Chung, Jeongsig Kim, Seob Jeon, Donghan Bae. Factors associated with HPV persistence after conization in patients with negative margins. J Gynecol Oncol 2009; 20(2):91-95.
136. Paraskevaidis E, Jandial L, Mann EMF, Fisher PM, Kitchener HC. Pattern of treatment failure following laser for cervical intraepithelial neoplasia:Implications for follow-up protocol. Obstet Gynecol 1991;78:80-3.
137. Cecchini S, Visioli CB, Zappa M, Ciatto S. Recurrence after treatment by loop electrosurgical excision procedure (LEEP) of high-grade cervical intraepithelial neoplasia.Tumori 2002; 88(6):478-80.
138. Ghaem-Maghami S, Sagi S, Majeed G, Soutter WP. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure:a meta-analysis. Lancet Oncol 2007;8:985-993.
139. Jakus S, Edmonds P, Dunton C, King SA. Margin status and excision of cervical intraepithelial neoplasia:a review. Obstet Gynecol Surv 2000;55:520-7.
140. Costa S, De Simone P, Venturoli S, Cricca M, Zerbini ML, Musiani M, et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol Oncol 2003;90:358-65.
141. Houfflin Debarge V, Collinet P, Vinatier D, Ego A, Dewilde A, Boman F, et al. Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. Gynecol Oncol 2003;90:587-92.
142. Brockmeyer AD, Wright JD, Gao F, Powell MA. Persistent and recurrent cervical dysplasia after loop electrosurgical excision procedure. Am J Obstet Gynecol 2005;192:1379-81.
143. Paraskevaidis E,Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN:a systematic review of the literature. Cancer Treat Rev 2004;30:205-11,
144. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, et al. HPV testing and monitoring of women after treatment of CIN 3:review of the literature and meta-analysis. Obstet Gynecol Surv 2004;59:543-53.
145. Aerssens A, Claeys P, Beerens E, Garcia A, Weyers S, Van Renterghem L, et al. Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia.Cytopathology 2009; 20(1):27-35.
146. Sarian LO, Derchain SF, Andrade LA, Tambascia J, Morais SS, Syrjanen KJ. HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2004; 94(1):181-6.
147. Alonso I, Tome A, Puig-Tintore LM, Esteve R, Quinto L, Campo E, et al. Pre-and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006;103:631-636.
148. Bae JH, Kim CJ, Park TC, Namkoong SE, Park JS. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. Int J Gynecol Cancer 2007;17:1271-1277.
149. Sarian LO, Derchain SF, Pitta Dda R, Morais SS, Rabelo-Santos SH. Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ). J Clin Virol 2004;31:270-274.
150. Soutter WP, de Barros Lopes A, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997;349:978-980.
151. Song SH, Lee JK, Oh MJ, Hur JY, Na JY, Park YK, et al. Persistent HPV infection after conization in patients with negative margins. Gynecol Oncol 2006;101:418-422.
152. Park JY, Lee KH, Dong SM, Kang S, Park SY, Seo SS. The association of pre-conization high-risk HPV load and the persistence of HPV infection and persistence/recurrence of cervical intraepithelial neoplasia after conization. Gynecol Oncol 2008;108:549-554.
153. Rousseau MC, Abrahamowicz M, Villa LL, Costa MC, Rohan T E, Franco EL.Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2003;12:1029-37.
154. Gargiulo F, Francesco MD, Schreiber C, Ciravolo G, Salinaro F, Valloncini B,et al. Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women.Virus Res 2007; 125(2):176-82.
155. Bachtiary B, Obermair A, Dreier B, Birner P, Breitenecker G, Knocke T H, et al. Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. Int. J. Cancer 2002; 102,237-243.
156. Munagala R, Dona MG, Rai SN, Jenson AB, Bala N, Ghim SJ, et al. Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response. Int J Oncol 2009; 34(1):263-71.
1. Parkin DM, BrayF, Ferlay J, Pisani P. Global cancer statistics 2002[J]. CA Cancer J Clin,2005,55(2):74-108.
2.郎景和.迎接子宫颈癌预防的全球挑战与机遇.中华妇产科杂志[J],2002；37(3)：129-131.
3.Munoz N, Bosch Fx, Sanjose S, et al. Epidemiologie classification of human papilloma virus types associated with cervical cancer[J]. N Engl J Med,2003,348:8.
4. Bosch FX, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer:a world perspective [J]. J of the Natinal Cancer Last,1995,87:796-802.
5. Sawe EI, Kjaer sk, Worm Am, et al. Risk factor for genital HPV DNA in men resemb ler thosefound in women:a study of male attendees at a Danish STD clinic[J]:Sex Transan Infect,2002,78:5.
6. Vddman T, Liu X, Yuan H. et al. Human papillomavirus E6 and Myc proteins. associate in vivo and bind to and cooperatively activte the telomerase reverse transcriptase promoter[J]. Proc Natl Acad Sci USA,2003,100(14):8211.
7. Gewin L, Galloway DA. E Box-dependent activation of telomerase by human papillomavirus type16 E6 does not require induction of c-myc[J]. J Virol,2001, 75(15):7198-7201.
8. Pao CC, ISeng CJ, Lm CY, et al. Diferent expression of telomerase activity in human cervical intraepithelial neoplasia lesions[J]. J Clin Oncol,1997,15(5):19-32.
9. Won J, Yin J, Kim TK. Oppllsing regulatory roles of E2F in human telomerase reverse teanscriptase(hTERT)gene expression in human tumor and nomal somatic ceils[J]. J FASEB,2002,16(14):1943-1945.
10. Boldrini L, Faviana P, Gisfredi S, et al. Regulation of telomerase its hTERT messenger in colorectal cancer[J]. Oncol Rep,2004,11(2):395-400.
11. Crish JF, Bone F, Balasubramainian S, et al. Suprabasal expression on the human papillomavirus type 16 onconproteins in mouse epidermis alters expression of cell cycle regulatory proteins. Carcinogenesis,2000,21(5):1031-1037
12. Kang YH, Lee KA, Ryu CJ, et al. Mitomycin C induces apoptois via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells[J]. Cancer Lett,2006,237(1):33-34.
13. Hubert P, Caberg JH, Gilles C, et al. E-cadherin-dependent adhesion of dendritic and Langerhans cells to keratinocytes is dfective in cervical human papillomavirus-associated (pre)neoplastic lesions [J]. J Pathol,2005,206(3): 346-355.
14. Clavel C, Masure M, Le vert M, et al. Human papillomavirus detection by the hybrid capture Ⅱ assay:a reliable test to select women with normal cervical smears at risk for developing cervieal lesions. Diagn Mol Pathol,2000,9 (3):145-150.
15.陶萍萍,卞美潞,欧华等.导流杂交基因芯片技术在人乳头状瘤病毒检测中 应用的研究[J].中华妇产科杂志,2006,41(1)：43-47.
16. Nardeli-Haefliger D, WirthnerD, Schiler JT, etal. Specific antibody levels at the cervix during the menstrual cycle of women vaccined with human papilomavirus 16 virus-like particles. Natl Cancer Inst.2003.95:1128-1137.
17.Koutsky LA, Ault KA, W heeler CM, et al. Proof of Principle Study Investigators:A controled trial of a human papillomavirus type 16 vaccine. N Engl J Med,2002,347(21):1645 - 1651.
18. Auh KA, Giuliano AR, Edwards RP, et al. A phasel study to evaluate a human papilomavirus(HPV)type 18 L1 VLP vaccine. Vaccine,2004.22(23-24):3004-3007.
19. Vilia LL. Costa RL. Petta CA. et al. Prophylactic quadrivalent human papillomavirus(types 6, 11,16and18)L1 virus-like particle vaccine in young women:a randomized double-blind placebo-controled muticentre phase Ⅱ efficacy trial. Lancet Oncol.2005,6:256-257.
20. Harper DM, Franco EL, W heeler C, et al. Eficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 an d 18 in young women:a randomised controled trial. Lancet,2004,364:1731-1732.
21. Muler M, Zhou J, Reed TD, et al. Chimeric papillomavirus-like particles. Virology.1997,234:93-111.
22. Moniz M, Ling M, Hung CF, et al. HPV DNA vaccines. Front Biosci,2003,8: 55-68.
23. Brinkman JA, Caffrey AS, Muderspach LI, et al. The impact of antiHPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol,2005,26(2):129-142.
24. Harper DM, Fran coEL, W heeler CM, et al. Sustained efficacy upto 4.5 years of a bivalent L1 virus-like particle vaccine against human papilomavirus types 16 and 18:follow-up from a randomized controled trial. Lancet.2006,367:1247-1255.